These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
685 related articles for article (PubMed ID: 15667617)
1. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab. Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617 [TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil without antibody induction in cadaver vs. living donor pediatric renal transplantation. Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; Hasan SM; Concepcion W Pediatr Transplant; 2003 Apr; 7(2):137-41. PubMed ID: 12654055 [TBL] [Abstract][Full Text] [Related]
3. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149 [TBL] [Abstract][Full Text] [Related]
4. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406 [TBL] [Abstract][Full Text] [Related]
6. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen. Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938 [TBL] [Abstract][Full Text] [Related]
7. Basiliximab induction in renal transplantation: long-term outcome. Atlani M; Sharma RK; Gupta A Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617 [TBL] [Abstract][Full Text] [Related]
8. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
9. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study. Gentile G; Somma C; Gennarini A; Mastroluca D; Rota G; Lacanna F; Locatelli B; Remuzzi G; Ruggenenti P Am J Nephrol; 2015; 41(1):16-27. PubMed ID: 25612603 [TBL] [Abstract][Full Text] [Related]
10. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205 [TBL] [Abstract][Full Text] [Related]
11. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Neu AM; Ho PL; Fine RN; Furth SL; Fivush BA Pediatr Transplant; 2003 Jun; 7(3):217-22. PubMed ID: 12756047 [TBL] [Abstract][Full Text] [Related]